Adipocyte REVERBa dictates adipose tissue expansion during obesity

A. Louise Hunter¹, Charlotte E. Pelekanou¹, Nicholas J. Barron¹, Rebecca C. Northeast¹, Antony Adamson¹, Polly Downton¹, Thomas Cornfield², Peter S. Cunningham¹, Leanne Hodson², Andrew S.I. Loudon¹, Richard D. Unwin³, Mudassar Iqbal⁴, David W. Ray², David A. Bechtold¹

1. Centre for Biological Timing, Faculty of Biology, Medicine and Health, University of Manchester
2. Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, and NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital
3. Stoller Biomarker Discovery Centre, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester
4. Division of Informatics, Imaging & Data Sciences, Faculty of Biology, Medicine and Health, University of Manchester
5. These authors contributed equally

Correspondence:
David A. Bechtold, 3.002 AV Hill Building, University of Manchester, Manchester, M13 9PT, UK; David.Bechtold@manchester.ac.uk, Tel: +44(0)161 2755721

Keywords: Circadian clock, energy metabolism, obesity, metabolic disease, adipose, nuclear hormone receptor, NR1D1, extracellular matrix
ABSTRACT

The circadian clock component REVERBα is considered a dominant regulator of lipid metabolism, with global Reverba deletion driving dysregulation of white adipose tissue (WAT) lipogenesis and obesity. However, a similar phenotype is not observed under adipocyte-selective deletion (Reverba\textsuperscript{Flox2-6 Adipo\textsuperscript{Cre}}), and transcriptional profiling demonstrates that, under basal conditions, direct targets of REVERBα regulation are limited, and include the circadian clock and collagen dynamics. Under high-fat diet (HFD) feeding, Reverba\textsuperscript{Flox2-6 Adipo\textsuperscript{Cre}} mice do manifest profound obesity, yet without the accompanying WAT inflammation and fibrosis exhibited by controls. Integration of the WAT REVERBα cistrome with differential gene expression reveals broad control of metabolic processes by REVERBα which is unmasked in the obese state. Adipocyte REVERBα does not drive an anticipatory daily rhythm in WAT lipogenesis, but rather modulates WAT activity in response to alterations in metabolic state. Importantly, REVERBα action in adipocytes is critical to the development of obesity-related WAT pathology and insulin resistance.
INTRODUCTION

The mammalian circadian clock directs rhythms in behaviour and physiology to coordinate our biology with predictable changes in food availability and daily alternations between fasted and fed states. In this way, profound cycles in nutrient availability and internal energy state can be managed across multiple organ systems. A central circadian clock in the suprachiasmatic nuclei (SCN) drives daily rhythms in our behaviour (e.g. sleep/wake cycles) and physiology (e.g. body temperature), and orchestrates rhythmic processes in tissue systems across the body (Dibner et al., 2010; West and Bechtold, 2015). The molecular clock mechanism is also present in most cells and tissue. Normal peripheral tissue function and expression of a ‘complete’ rhythmic transcriptome requires local tissue clock activity, as well as input from the central clock and rhythmic systemic signals (Guo et al., 2005; Hughes et al., 2012; Kornmann et al., 2007; Koronowski et al., 2019; Lamia et al., 2008). The relative importance of each of these factors remains ill-defined. Nevertheless, it is clear that our rhythmic physiology and metabolic status reflects the interaction of clocks across the brain and body (West and Bechtold, 2015). Disturbance of this interaction, as occurs with shift work and irregular eating patterns, is increasingly recognised as a risk factor for metabolic disease and obesity (Broussard and Cauter, 2016; Kim et al., 2019).

Extensive work over the past 20 years has demonstrated that circadian clock function and its component factors are closely tied into energy metabolism (Bass and Takahashi, 2010; Reinke and Asher, 2019), with strong rhythmicity evident in cellular and systemic metabolic processes. Clock-metabolic coupling in peripheral tissues is adaptable, as demonstrated by classical food-entrainment studies (Damiola et al., 2000; Mistlberger, 1994), and by recent work showing that systemic perturbations such as cancer and high-fat diet feeding can re-programme circadian control over liver metabolism (Dyar et al., 2018; Masri et al., 2016). Plasticity therefore exists within the system, and the role of the clock in tissue and systemic responses to acute and chronic metabolic perturbation remains a critical question. The nuclear
receptor REVERBα (NR1D1) is a core clock component, and has been highlighted as a key link between the clock and metabolism. REVERBα is a constitutive repressor, with peak expression in the latter half of the inactive phase (daytime in the nocturnal animal). In liver, REVERBα exerts repressive control over programmes of lipogenesis by recruiting the NCOR/HDAC3 co-repressor complex to metabolic target genes, such that loss of REVERBα or HDAC3 results in hepatosteatosis (Feng et al., 2011; Zhang et al., 2016, 2015). The selective functions of REVERBα in white adipose tissue (WAT) are not well-established and remain poorly understood. Early studies implicated an essential role of Reverba in adipocyte differentiation (Chawla and Lazar, 1993; Kumar et al., 2010); however, these findings are difficult to align with in vivo evidence. Indeed, pronounced adiposity and adipocyte hypertrophy are evident in Reverba−/− mice, even under normal feeding conditions (Delezie et al., 2012; Hand et al., 2015; Zhang et al., 2015). Moreover, daily administration of REVERBα agonists has been shown to reduce fat mass and WAT lipogenic gene expression in mice (Solt et al., 2012), despite concerns about off-targets actions of these agents (Dierickx et al., 2019). Given the links between circadian disruption and obesity, and the potential of REVERBα as a pharmacological target, we now define the role of REVERBα in dictating WAT metabolism.

Transcriptomic and proteomic profiling of WAT in global Reverba−/− mice revealed an expected de-repression of lipid synthesis and storage programmes. However, in contrast, selective deletion of Reverba in adipocytes did not result in dysregulation of WAT metabolic pathways. Loss of REVERBα activity in WAT did, however, significantly enhance adipose tissue expansion in response to HFD feeding; yet despite the exaggerated obesity, adipocyte-specific knockout mice were spared anticipated obesity-related pathology. Integration of transcriptomic data with the WAT REVERBα cistrome demonstrates that, under basal conditions, REVERBα activity is limited to a small set of direct target genes (enriched for extracellular matrix processes). However, REVERBα-regulatory control broadens to include lipid and mitochondrial metabolism pathways under conditions of obesity. Our data recast the role of
REVERBα as a regulator responsive to the metabolic state of the tissue, rather than one which delivers an anticipatory daily oscillation to the WAT metabolic programme.
RESULTS

Adiposity and up-regulation of WAT lipogenic pathways in Reverba\textsuperscript{−/−} mice

We first examined the body composition of age-matched Reverba global knockout (KO) (Reverba\textsuperscript{−/−}) mice and littermate controls (WT). In keeping with previous reports (Delezie et al., 2012; Hand et al., 2015), Reverba\textsuperscript{−/−} mice are of similar body weight to littermate controls (Figure 1A), yet carry an increased proportion of fat mass (KO: 24.2 ±3.0\% of body weight; WT: 10.8 ±1.4\%; mean ±SEM, P<0.01 Student’s t-test, n=12-14/group) and display adipocyte hypertrophy (Figure 1B), even when maintained on a standard chow diet. Metabolic phenotyping demonstrated expected day-night differences in food intake, energy expenditure, activity, and body temperature in both KO and WT controls, although genotype differences in day/night activity and temperature levels suggest some dampening of rhythmicity in the Reverba\textsuperscript{−/−} mice (Figure 1 Supplemental A-E). However, this is unlikely to account for the increased adiposity in these animals, and a previous study did not report significant genotype differences in these parameters (Delezie et al., 2012). This favours instead an altered energy partitioning within these mice, with a clear bias towards storing energy as lipid.

To explore further the lipid storage phenotype, we undertook proteomic analysis of gonadal white adipose tissue (gWAT) collected at ZT8 (zeitgeber time, 8h after lights on), the time of normal peak in REVERB\textsubscript{α} expression in this tissue (Figure 1 Supplemental F). Isobaric tag (iTRAQ) labelled LC-MS/MS identified 2257 proteins, of which 182 demonstrated differential regulation (FDR<0.05) between WT and Reverba\textsuperscript{−/−} gWAT samples (n=6 weight-matched, 13-week old male mice/group) (Figure 1C). Differentially expressed proteins included influential metabolic enzymes, with up-regulation of metabolic processes detected on pathway enrichment analysis (Figure 1D). Importantly, and in line with the phenotype observed, increased NADPH regeneration (e.g. ME1, G6PDX), enhancement of glucose metabolism, (also likely reflecting increased glyceroneogenesis; e.g. PFKL, ALDOA), and up-regulation of fatty acid synthesis (e.g. ACYL, FAS, ACACA) all support a shunt towards synthesis and...
FIGURE 1. Global deletion of Reverba results in obesity and increased adipose lipid synthesis.
A. Reverba−/− mice exhibit significantly greater fat mass relative to WT littermate controls. Body weight, fat mass and lean mass of 13-week old males (n=12-14/group). B. Increased fat mass in Reverba−/− mice is reflected in adipocyte hypertrophy in gonadal white adipose tissue (gWAT) (representative x10 H&E images shown). C,D. gWAT from Reverba−/− mice exhibits a programme of increased lipid synthesis. Proteomic profiling of gWAT depots (Reverba−/− mice plotted relative to their respective weight-matched littermate controls, n=6/group (C)) shows deregulation of metabolic regulators and enrichment (D) of metabolic pathways (up- and down-regulated proteins shown in blue and red respectively). Top five (by protein count) significantly enriched Reactome terms shown. E. Analyses of fatty acid (FA) composition reveal increased de novo lipogenesis (reflected by C16:0/C18:2n ratio) and FA desaturation (reflected by C16:1n-7/C16:0 ratio) in gWAT of Reverba−/− mice. n=6/group.

Data presented as mean with individual data points (A, E). *P<0.05, **P<0.01, unpaired two-tailed t-test (A, E).
FIGURE 1 SUPPLEMENTAL. Rhythmic physiology and susceptibility to diet-induced obesity in *Reverba*^−/−^ mice.

A-E. Under light:dark conditions, *Reverba*^−/−^ mice maintain robust diurnal rhythms in physiology and behaviour. Day/night food intake (A) (n=12-14/group), and energy expenditure (B) (n=3-4/group). Diurnal activity profile, mean activity (C) and body temperature (D) of adult male *Reverba*^−/−^ mice (activity is reported as the % daily activity, n=9-13/group). Diurnal profiles in oxygen consumption (VO₂) and carbon dioxide production (VCO₂) (E) (n=9-13/group). F. Western blot showing REVERBa expression in adipose tissue over 24 hours. G. Molar percentages of fatty acid species in WT and *Reverba*^−/−^ gWAT. n=6/group. *P<0.05. H. Daytime (ZT6) fasted blood glucose levels (n=11/group). I. *Reverba*^−/−^ mice are highly susceptible to diet-induced obesity, showing significantly higher body weights and fat mass than control mice after 10 weeks of HFD feeding (n=6/group). J. In a separate study, food intake was tracked for individual mice over 3 weeks of HFD feeding (n=13/group). Mean daily food intake in *Reverba*^−/−^ mice showed a significant positive correlation with body weight.

Data presented as individual data points with mean (A-D, H, I), as mean +/- SEM (F), or as individual data points with line of best fit (J). **P<0.01, two-way ANOVA with Tukey’s multiple comparisons tests (A-D), unpaired t-tests with correction for multiple testing (G), unpaired two-tailed t-tests (H,I), linear regression (J).
storage of fatty acids and triglyceride in the knockout mice. To validate this putative increase in local lipid synthesis, we quantified fatty acid species in gWAT, and indeed, the ratio of palmitic to linoleic acid (C16:0/C18:2n6), a marker of de novo lipogenesis, was significantly elevated in Reverba<sup>−/−</sup> samples (Figure 1E, Figure 1 Supplemental G). Fatty acid profiling also revealed evidence of increased SCD1 activity (C16:1n-7/C16:0). Enhanced fatty acid synthesis in gWAT of mice lacking REVERBα may be in part driven by increased glucose availability and adipose tissue uptake as previously suggested (Delezie et al., 2012), although we do not observe elevated blood glucose levels in the Reverba<sup>−/−</sup> animals (Figure 1 Supplemental H). The propensity to lipid storage is further highlighted by the substantial obesity, compared to littermate controls, displayed by Reverba<sup>−/−</sup> mice when challenged with 10 weeks of high-fat diet (HFD) (Figure 1 Supplemental I; Delezie et al., 2012; Hand et al., 2015). Interestingly, we observed a strong positive correlation between body weight and daily intake of HFD in the Reverba<sup>−/−</sup> mice (Figure 1 Supplemental J), suggesting that HFD-induced hyperphagia exacerbates weight gain and obesity in the Reverba<sup>−/−</sup> mice.

**Limited impact of adipocyte-selective Reverba deletion under basal conditions**

To define the role of REVERBα specifically within WAT, we generated a new mouse line with loxP sites flanking Revera exons 2-6 (Reverba<sup>Flox2-6</sup>), competent for Cre-mediated conditional deletion (Figure 2A; Hunter et al., 2020). We crossed this mouse with the well-established adiponectin Cre-driver line (Adipo<sup>Cre</sup>; Eguchi et al., 2011; Jeffery et al., 2014) to delete Reverba selectively in adipocytes. This new line results in loss of Reverba mRNA (Figure 2B) and protein (Figure 2C) expression in adipose tissue depots, as well as coordinate de-repression of Bmal1, upon Cre-mediated recombination.

In marked contrast to global Reverba<sup>−/−</sup> mice, adult Reverba<sup>Flox2-6</sup>Adipo<sup>Cre</sup> mice did not show an increase in adiposity when maintained on a standard chow diet (Figure 2D; n=7/group), with no differences in mean body weight, fat and lean mass observed. In parallel with this, we saw
FIGURE 2. Impact of adipose Reverba deletion is limited under normal conditions.
A. Targeting strategy for LoxP site integration flanking exons 2-6 of the Nr1d1 (Reverba) locus. B. Reverba and Bmal1 gene expression in gWAT, brown adipose (BAT), liver and lung in ReverbaFlox2-6 (Cre−ve) and ReverbaFlox2-6AdipoCre (Cre+ve) mice (n=4-5/group). C. REVERBa protein expression (arrowhead) in Cre−ve and targeted Cre+ve mice. Lower blot shows Ponceau S protein staining. D. Body weight, fat mass and lean mass in 13-week old Cre−ve and Cre+ve male mice (n=7/group). E-G. Both ReverbaFlox2-6AdipoCre Cre+ve and Cre−ve mice demonstrate diurnal rhythms in behaviour and physiology, with no genotype differences observed in food intake (E), energy expenditure and daily activity (F) or body temperature (G) in 13-week old males (n=4-7/group).

Data presented as mean +/- SEM (B,) or as mean with individual data points (D-G). *P<0.05, **P<0.01, unpaired t-tests corrected for multiple comparisons (B), unpaired t-tests (D), two-way ANOVA with Tukey’s multiple comparisons tests (E-G).
FIGURE 2 SUPPLEMENTAL. Loss of Reverbα expression in brown adipocytes does not alter body temperature.

A-B. Housing under standard laboratory conditions did not alter daily profiles in body temperature in the ReverbαFlox2-6AdipoCre Cre+ve mice, when compared to control Cre−ve littermate controls (A; n=5-6/group), despite showing increased UCP1 expression (B; n=3/group). C. No intergenotype genotype differences were observed in body temperature profiles recorded from mice housed under thermoneutral conditions (28-30°C) for 3 weeks (n=5-6/group). D-E. Brown adipose tissue (BAT) gene expression studies (qPCR) demonstrated expected de-repression of Bmal1 expression in Cre+ve mice, and expected reduction in Ucp1 expression at thermoneutral conditions in both genotypes (compared to room temperature) (n=5-6/group). F. ReverbαFlox2-6AdipoCre Cre+ve mice and control littermates were exposed to an acute cold challenge (4°C for 6 h) with body temperature recording throughout (n=5-6/group). No genotype difference in thermogenic response was observed. G-H. As previously reported, Reverbα expression was reduced by cold exposure; however, no genotype differences were observed cold-induced increases in Ucp1 or Dio2 gene expression (n=5-6/group).

Data presented as mean +/- SEM. *P<0.05, **P<0.01, Student’s t-test (B), 2-way ANOVA with Tukey’s multiple comparisons tests (D, E, G, H).
no differences in daily patterns of food intake, energy expenditure, activity levels or body temperature in matched $Reverba^{Flox2-6}\text{Adipo}^{\text{Cre}}$ and control ($Reverba^{Flox2-6}$) mice (Figure 2D,E).

As brown adipose tissue (BAT) makes an important contribution to whole body energy metabolism, we studied the thermoregulation of $Reverba^{Flox2-6}\text{Adipo}^{\text{Cre}}$ mice in greater detail.

It has previously been proposed that REVERBα is key in conferring circadian control over thermogenesis, through its repression of uncoupling protein 1 (UCP1) (Gerhart-Hines et al., 2013). However, we saw no genotype differences in thermoregulation between $Reverba^{Flox2-6}\text{Adipo}^{\text{Cre}}$ and $Reverba^{Flox2-6}$ mice (Figure 2 Supplemental A-E). Despite increased BAT UCP1 expression, no differences in body temperature profiles were observed between Cre−ve and Cre+ve mice when housed under normal laboratory temperature (~22ºC) nor when placed under thermoneutral conditions (29ºC) for >14days. Moreover, Cre−ve and Cre+ve mice did not differ in their thermogenic response to an acute cold challenge (4ºC for 6hr) (Figure 2 Supplemental F-H). Therefore, the minimal impact on body composition of adipose-targeted $Reverba$ deletion cannot be explained by altered BAT thermogenic activity, and moreover, these data challenge existing theories about the role of $Reverba$ in thermoregulation.

In normal WAT, REVERBα-regulated targets are limited to clock and collagen genes

To investigate adipocyte-specific $Reverba$ activity, we performed RNA-seq at ZT8 (n=6/group) in both $Reverba^{−/−}$ and $Reverba^{Flox2-6}\text{Adipo}^{\text{Cre}}$ mouse lines. Global $Reverba$ deletion had a large effect on the gWAT transcriptome, with 4163 genes showing significant differential expression (FDR<0.05) between $Reverba^{−/−}$ mice and age- and weight-matched WT littermate controls (Figure 3A). Pathway enrichment analysis demonstrated that these changes are dominated by metabolic genes (Figure 3B(i)), with lipid metabolism and the TCA cycle emerging as prominent processes (Figure 3B(ii)). Thus, the gWAT transcriptome in $Reverba^{−/−}$ mice is concordant with the phenotype, and the gWAT proteome, in demonstrating up-regulation of lipid accumulation and storage processes.
By contrast, and consistent with the absence of an overt phenotype, only a small genotype effect on the transcriptome was observed when comparing gWAT RNA-seq from Reverba$^{\text{Flox2-AdipoCre}}$ and Reverba$^{\text{Flox2-6}}$ littermates (Figure 3C; n=6/group). Here, 238 genes showed significant differential expression between genotypes, of which 128 were also differentially regulated in the WAT analysis of global Reverba$^{\text{+/+}}$ mice (Figure 3D). These 128 common genes included circadian clock components (Bmal1, Clock, Cry2, Nfil3), whilst pathway analysis also revealed collagen formation/biosynthesis processes to be significantly enriched (Figure 3C). Regulation of the molecular clock is expected, but the discovery of collagen dynamics as a target of REVERB$\alpha$ regulatory action in adipocytes has not been previously recognised. We validated consistent up-regulation of collagen and collagen-modifying genes in Reverba$^{\text{+/+}}$ and Reverba$^{\text{Flox2-6AdipoCre}}$ gWAT by qPCR (Figure 3F).

It is notable that Reverba$^{\text{Flox2-6AdipoCre}}$ mouse gWAT exhibits neither enrichment of lipid metabolic pathways, nor de-regulation of individual key lipogenic genes, previously identified as REVERB$\alpha$ targets (Figure 3E,G) (Feng et al., 2011; Zhang et al., 2016, 2015). These findings suggest lipogenic gene regulation may be a response to system-wide changes in energy metabolism in the Reverba$^{\text{+/+}}$ animals, and challenge current understanding of REVERB$\alpha$ action.

Work in liver has suggested that the REVERB$\alpha$ parologue, REVERB$\beta$, contributes to the suppression of lipogenesis, and that concurrent REVERB$\beta$ deletion amplifies the impact of REVERB$\alpha$ loss (Bugge et al., 2012). We therefore performed double knock-down of Reverba and Reverb$\beta$ in differentiated 3T3-L1 cells (Figure 3 Supplemental A). Whilst double knock-down produced greater Bmal1 de-repression than either Reverba or Reverb$\beta$ knock-down alone, it did not lead to de-repression of lipogenic genes previously considered REVERB$\alpha$ targets (Figure 3 Supplemental B). This suggests that compensation by Reverb$\beta$ does not underlie the mild phenotype observed in the Reverba$^{\text{Flox2-6AdipoCre}}$ mice.
**FIGURE 3.** Global or adipose-specific *Reverba* deletion produces distinctive gene expression profiles. A, B. *Reverba*−/− gWAT demonstrates extensive remodelling of the transcriptome and up-regulation of metabolic pathways. Mean-difference (MD) plot (A) showing significantly (FDR<0.05) up- (blue) and down- (red) regulated genes in gWAT of *Reverba*−/− mice compared to littermate controls (n=6/group). Pathway analysis (B) of significantly differentially expressed genes (FDR<0.05): top five (by gene count) significantly enriched Reactome terms shown (B(i)), top 5 metabolic pathways shown (B(ii)). Up-regulated genes in blue, down-regulated in red. ODC = ornithine decarboxylase. C. By contrast, RNA-seq demonstrates modest remodelling of the transcriptome in gWAT of *Reverba*^Flox2-6*AdipoCre* mice. MD plot, n=6/group. D. Venn diagram showing overlap of differentially-expressed (DE) genes in *Reverba*^Flox2-6*AdipoCre* and *Reverba*−/− gWAT. E. Pathway analysis of 128 commonly DE genes. Top five (by gene count) significantly enriched Reactome terms shown. F,G. Collagen genes are commonly up-regulated in both genotypes (F), whilst genes of lipid metabolism are not DE in *Reverba*^Flox2-6*AdipoCre* (G). gWAT qPCR, n=6-7/group.

Data presented as mean +/- SEM (F, G). *P<0.05, **P<0.01, unpaired t-tests corrected for multiple comparisons (F, G).
FIGURE 3 SUPPLEMENTAL. Impact of \textit{Reverba} and \textit{Reverb\beta} loss \textit{in vitro}.

\textbf{A, B}. Double knockdown of \textit{Reverba} and \textit{Reverb\beta} in differentiated 3T3-L1 cells (\textbf{A}) results in marked de-repression of \textit{Bmal1} expression but minimal effects on expression of typically pro-lipogenic genes (\textbf{B}) (data compiled from three replicated knockdown experiments, n=8-9/treatment group).

Data presented as mean +/- SEM. *\textit{P}<0.05, **\textit{P}<0.01, one-way ANOVA with Dunnett's multiple comparisons tests (\textbf{A, B}).
Thus, whilst global REVERB\(\alpha\) targeting produces an adiposity phenotype with up-regulation of WAT lipogenesis and lipid storage, this is not seen when REVERB\(\alpha\) is selectively targeted in adipose alone. The distinction is not due to loss of Reverba expression in brown adipose, and is not due to compensatory REVERBB action. Taken together, our data suggest that under a basal metabolic state, the adipose transcriptional targets under direct REVERB\(\alpha\) control are in fact limited to core clock function and collagen dynamics. REVERB\(\alpha\) is not a major repressor of lipid metabolism in this setting. This also suggests that the enhanced lipid accumulation phenotype of Reverba\(^{-}\) adipose tissue is either independent from adipose REVERB\(\alpha\) entirely, or that the action of REVERB\(\alpha\) in adipose is context-dependent.

Diet-induced obesity reveals a broader WAT phenotype in tissue-specific REVERB\(\alpha\) deletion

Studies in liver tissue have demonstrated reprogramming of both nuclear receptor and circadian clock factor activity by metabolic challenge (Eckel-Mahan et al., 2013; Goldstein et al., 2017; Guan et al., 2018; Quagliarini et al., 2019). Both our data here, and previous reports (Delezie et al., 2012; Feng et al., 2011; Hand et al., 2015; Le Martelot et al., 2009; Preitner et al., 2002), highlight that the normal chow-fed Reverba\(^{-}\) mouse is metabolically abnormal. The emergence of the collagen dynamics as a direct REVERB\(\alpha\) target and exaggerated diet-induced obesity evident in Reverba\(^{-}\) mice supports a role for REVERB\(\alpha\) in regulating adipose tissue expansion under obesogenic conditions. To test this, Reverba\(^{\text{Flox2-6 AdipoCre}}\) and Reverba\(^{\text{Flox2-6}}\) mice were provided with HFD for 16 weeks to drive obesity and WAT expansion. Indeed, compared to their controls, Reverba\(^{\text{Flox2-6 AdipoCre}}\) mice exhibited greater weight gain and adiposity in response to HFD feeding (Figure 4A,B). Of note, divergence between control and Reverba\(^{\text{Flox2-6 AdipoCre}}\) mice became clear only after long-term HFD-feeding (beyond ~13 weeks), a time at which body weight gain plateaus in control mice. This contrasts substantially with Reverba\(^{-}\) mice, which show rapid and profound weight gain from the start of HFD feeding (Hand et al., 2015). The stark difference in progression and severity of diet-induced obesity is likely due (at least in part) to the HFD-induced hyperphagia, which is observed in Reverba\(^{-}\).
FIGURE 4. Diet-induced obesity unmasks a role for REVERBα in the regulation of adipose expansion.

**A, B.** High-fat diet leads to exaggerated adiposity in *Reverba<sup>Flox2-6 Adipo<sup>Cre</sup></sup> mice. Body weight track of Cre<sup>-ve</sup> and Cre<sup>+ve</sup> male mice on high-fat diet (solid line) or normal chow (dashed line) (**A**) (*P*<0.05: Cre<sup>+ve</sup> NC vs HFD; b*P*<0.05, Cre<sup>-ve</sup> NC vs HFD; c*P*<0.05, Cre<sup>+ve</sup> HFD vs Cre<sup>-ve</sup> HFD); total body, fat and lean weight after 16 weeks in the high-fat diet group (**B**). **C.** On histological examination of WAT, HFD-fed Cre<sup>+ve</sup> mice display less fibrosis and inflammation than Cre<sup>-ve</sup> littermates. Representative Picrosirius Red and F4/80 immunohistochemistry images (x20 magnification) (**C**), quantification of staining across groups, each data point represents the mean value for each individual animal (**D**). **E, F.** Despite increased adiposity, HFD-fed Cre<sup>+ve</sup> mice display greater insulin sensitivity than Cre<sup>-ve</sup> controls. Terminal blood glucose and insulin levels (animals culled 2hrs after food withdrawal) in NC and HFD-fed in *Reverba<sup>Flox2-6 Adipo<sup>Cre</sup></sup> (black) and Cre<sup>-ve</sup> (orange) mice (**E**). Blood glucose values for individual animals and area within curve for 16-week HFD-fed *Reverba<sup>Flox2-6 Adipo<sup>Cre</sup></sup> Cre<sup>-ve</sup> and Cre<sup>+ve</sup> mice undergoing insulin tolerance testing (ITT) (**F**).

Data presented as mean +/- SEM (**A**) or as individual data points with mean (**B, D, E, F**). *P*<0.05, **P**<0.01, two-way repeated measures ANOVA with Tukey’s multiple comparisons tests (**A**), two-way ANOVA with Sidak’s multiple comparisons tests (**D, E**), unpaired two-tailed t-test (**B, F**). n=4-11/group for all panels.
FIGURE 4 SUPPLEMENTAL. Adipocyte size in *Reverba*<sup>Flox2-6</sup> and *Reverba*<sup>Flox2-6 Adipo<sup>C</sup>re</sup> mice. 

A. Quantification of WAT adipocyte size in NC- and HFD-fed *Reverba*<sup>Flox2-6</sup> and *Reverba*<sup>Flox2-6 Adipo<sup>C</sup>re</sup> mice demonstrates no between-genotype differences in size distribution. n=4-6/group.

Data presented as mean. Two-way ANOVA with Tukey’s multiple comparisons tests.
mice (WT food intake $2.92 \pm 0.10g$ HFD/day/mouse; KO $3.74 \pm 0.21g$, $P=0.0014$, Student’s T-test, n=21/genotype), but not in $Reverba^{Flox2-6 Adipo^{Cre}}$ mice (Cre$^{-ve}$ $2.99 \pm 0.61g$ HFD/day/mouse; Cre$^{+ve}$ $3.01 \pm 0.60g$, $P>0.05$, n=8/genotype). Nevertheless, both models highlight that loss of REVERBa increases capacity for increased lipid storage and adipose tissue expansion under obesogenic conditions.

Despite the enhanced diet-induced obesity, HFD-fed $Reverba^{Flox2-6 Adipo^{Cre}}$ mice showed little evidence of typical obesity-related pathology. Histological assessment of gWAT after 16-weeks of HFD feeding revealed widespread adipose tissue fibrosis (Picrosirius Red staining of collagen deposition under normal and polarised light) and macrophage infiltration (F4/80 immunohistochemistry) in obese control mice, but these features were not seen in $Reverba^{Flox2-6 Adipo^{Cre}}$ mice (Figure 4C,D). Furthermore, we saw evidence of preserved insulin sensitivity in the HFD-fed $Reverba^{Flox2-6 Adipo^{Cre}}$ mice, with neither circulating glucose nor insulin being higher than $Reverba^{Flox2-6}$ littermate controls (Figure 4E), despite carrying significantly greater fat mass. Indeed, on insulin tolerance testing, HFD-fed $Reverba^{Flox2-6 Adipo^{Cre}}$ mice demonstrated more marked hypoglycaemia than HFD-fed controls (Figure 4F).

We saw no differences in adipocyte size between the two genotypes, indicating that our observations did not simply reflect greater adipocyte hyperplasia in the $Reverba^{Flox2-6 Adipo^{Cre}}$ mice (Figure 4 Supplemental A).

Therefore, under long-term HFD-feeding conditions, adipose-targeted $Reverba$ deletion results in continued adipose tissue expansion accompanied by a healthier metabolic phenotype with reduced adipose inflammation and fibrosis, and preserved systemic insulin sensitivity. Importantly, these findings also suggest that the regulatory influence of REVERBa is context-dependent, with the metabolic impact of adipose-targeted $Reverba$ deletion revealed by transition to an obese state.

$REVERB\alpha$-dependent gene regulation is reprogrammed by obesity
We next performed RNA-seq on gWAT collected at ZT8 from \textit{Reverba}^{\text{Flox2-6}} \textit{Adipo}^{\text{Cre}} and \textit{Reverba}^{\text{Flox2-6}} littermate controls fed either normal chow (NC) or HFD for 16 weeks (NC, n=4/group; HFD, n=6/group). As expected, HFD-feeding had a substantial impact on the gWAT transcriptome in both Cre$^{-}$ and Cre$^{+}$ animals (i.e. NC vs HFD comparison within each genotype; Figure 5A). Under NC feeding conditions, we again observed only a small genotype effect on the transcriptome, and as before, differentially-expressed genes included core clock genes (\textit{Bmal1}, \textit{Nfil3}, \textit{Npas2}, \textit{Clock}) and those of collagen synthesis pathways (Figure 5B).

However, obesity revealed a substantial genotype effect, with 3061 genes differentially expressed (1706 up, 1355 down) in HFD-fed \textit{Reverba}^{\text{Flox2-6}} \textit{Adipo}^{\text{Cre}} mice versus HFD-fed \textit{Reverba}^{\text{Flox2-6}} controls (Figure 5B), and 1704 genes showing a significant ($\alpha<0.05$) diet-genotype interaction (stageR specific interaction analysis; Van den Berge et al., 2017). Of these 1704 genes, those up-regulated in obese \textit{Reverba}-deficient adipose were strongly enriched for metabolic pathways, whilst down-regulated genes showed weak enrichment of ECM organisation processes (Figure 5C). To examine how loss of \textit{Reverba} alters adipose tissue response to diet-induced obesity, we compared directly those processes which showed significant obesity-related dysregulation in control mice (Figure 5D). While HFD-feeding caused a profound down-regulation (vs NC conditions) of metabolic pathways in the WAT of control mice, this was not observed in \textit{Reverba}^{\text{Flox2-6}} \textit{Adipo}^{\text{Cre}} mice. By contrast, HFD-feeding led to an up-regulation of immune pathways in both genotypes (Figure 5D). Thus, transcriptomic profiling correlates with phenotype in suggesting that WAT function and metabolic activity is protected from obesity-related dysfunction in the \textit{Reverba}^{\text{Flox2-6}} \textit{Adipo}^{\text{Cre}} mice, and that the impact of adipose \textit{Reverba} deletion is dependent on system-wide metabolic state.

Integration of differential gene expression with the WAT cistrome reveals state-dependent regulation of metabolic targets by REVERB$\alpha$

To examine the mechanism of REVERB$\alpha$ regulation of the WAT metabolic programme in HFD-fed mice, we analysed the relationship between differentially expressed genes revealed by
Under conditions of obesity, REVERBα repression extends to metabolic pathways.

A. High-fat diet dramatically remodels the WAT transcriptome. RNA-seq (n=4-6/group) was performed in gWAT from Cre<sup>−ve</sup> and Cre<sup>ve</sup> male mice fed normal chow (NC) or high-fat diet (HFD) for 16 weeks. MD plots show genes significantly (FDR<0.05) up-regulated (blue) or down-regulated (red) by HFD in each genotype. B. With HFD, the REVERBa-responsive gWAT transcriptome broadens. MD plots show effect of genotype in NC (top panel) and HFD (lower panel) feeding conditions. Genes where stageR detects a significant (α=0.05) genotype-diet interaction highlighted in orange. C. Reactome pathway analysis of genes up- or down-regulated in Cre<sup>ve</sup> gWAT under HFD conditions, where this diet-genotype interaction is also detected. Top five (by gene count) significantly enriched terms shown. D. Adipose-targeted deletion of Reverbα attenuates the normal HFD-induced down-regulation of metabolic pathways. Heatmaps show enrichment (-log<sub>10</sub>(padj)) of Reactome pathways in genes up-regulated (left) or down-regulated (right) by HFD feeding in Cre<sup>−ve</sup> and Cre<sup>ve</sup> gWAT. Top twenty (by gene count in Cre<sup>ve</sup> group) significantly enriched terms shown.
our RNA-seq studies and the WAT REVERBα cistrome. We identified primary REVERBα target genes by comparing genes changing in \( \text{Reverb}^{\text{Flox2-6\,Adipo}\text{Cre}} \) gWAT (relative to control mice, under both NC and HFD conditions) with genes changing in \( \text{Reverb}^{-/-} \) gWAT. To define the cistrome, we used raw published gWAT ChIP-seq data (Zhang et al., 2015) to call 2,354 high-stringency REVERBα peaks. To infer which genes might be direct targets of REVERBα repression, we employed a custom Python script that calculates the enrichment of differentially expressed gene sets in spatial relation to identified transcription factor binding sites (Figure 6 Supplemental A) (Hunter et al., 2020; Yang et al., 2019), over all genes in the genome.

Under NC conditions, only small sets of genes were up- or down-regulated in both \( \text{Reverb}^{\text{Flox2-6\,Adipo}\text{Cre}} \) and \( \text{Reverb}^{-/-} \) tissues (versus their respective controls) (Figure 6A(i,ii)). Nevertheless, genes up-regulated in \( \text{Reverb}^{\text{Flox2-6\,Adipo}\text{Cre}} \) and \( \text{Reverb}^{-/-} \) gWAT were significantly enriched around REVERBα ChIP-seq peaks at distances up to 1Mbp (Figure 6A(i)), consistent with repression mediated directly by DNA-bound REVERBα. Of these genes, 61.8% were within 100kbp of a stringent REVERBα peak, strongly suggesting that this gene cluster (clock and collagen genes) represents direct targets of REVERBα repression in WAT under NC conditions. Genes up-regulated only in \( \text{Reverb}^{-/-} \) WAT were also enriched around REVERBα peaks (at distances of up to 500kbp) suggesting that at least a proportion of these genes are presumptive direct targets of REVERBα regulation. In contrast, no enrichment of genes with decreased expression in \( \text{Reverb}^{\text{Flox2-6\,Adipo}\text{Cre}} \) or \( \text{Reverb}^{-/-} \) WAT was evident at any distance from REVERBα peaks (Figure 6A(ii)). Thus, REVERBα activation of transcription involves a different mechanism of regulation, likely involving secondary or indirect mechanisms (e.g. de-repression of another repressor), as previously proposed to explain REVERBα transactivation (Le Martelot et al., 2009).

HFD-feeding of \( \text{Reverb}^{\text{Flox2-6\,Adipo}\text{Cre}} \) mice greatly increased the overlap of differentially-expressed genes with those differentially expressed in \( \text{Reverb}^{-/-} \) WAT. (Figure 6A(iii,iv)). We observed a highly significant proximity enrichment of these commonly up-regulated genes
(863) to sites of REVERBα chromatin binding (Figure 6A(iii)), but again, saw no enrichment of the commonly down-regulated genes (Figure 6A(iv)). This integration of transcriptome and cistrome profiling suggests that REVERBα’s exertion of direct repressive control over gene targets is dependent on metabolic state, and increases substantially under HFD-feeding conditions. Of note, the 1714 genes up-regulated only in the Reverbα-/−WAT retained some proximity enrichment to REVERBα binding sites. This suggests that some of these genes are direct REVERBα targets but subject to additional transcriptional controls.

Consistent with the healthier metabolic phenotype and transcriptome changes observed in obese ReverbαFlox2-6 AdipoCre mice, we found that the large majority of the 863 REVERBα gene targets unmasked by HFD-feeding are normally repressed in obesity (Figure 6B), with 551 (63.8%) being significantly down-regulated in obese control (Cre−/−) animals. These genes include important regulators of lipid and mitochondrial metabolism (Figure 6C) - including Fasn, Scd1, Dgat2, Cs - and FGF-21 co-receptor Klb, a previously-identified REVERBα target gene (Jager et al., 2016). Considered together, these findings suggest that the healthy adiposity phenotype in HFD-fed ReverbαFlox2-6 AdipoCre mice results from de-repression of REVERBα-controlled pathways allowing continued and efficient lipid synthesis and storage, thus permitting greater expansion of the adipose bed and attenuation of obesity-related dysfunction.
A. Genes commonly up-regulated by Reverb loss, in both the basal and obese state, show the strongest association with gWAT REVERBα ChIP-seq peaks. Venn diagrams show overlap of differentially-expressed (DE) genes in ReverbαFlox2-6AdipoCre Cre+ve mice (under NC (i, ii) and HFD (iii, iv) conditions) with differentially-expressed genes in Reverbα-/- mice (each compared to their respective controls). Plots show –log10(P-value for enrichment) for each gene cluster at increasing distances from stringent REVERBα gWAT ChIP-seq peaks (FE>7.5 over input). See Figure 6 Supplemental (A) for schematic. DE genes separated by direction of regulation (up or down). B, C. REVERBα targets are also down-regulated in obesity, and include important lipid and mitochondrial metabolic regulators. Volcano plot (B) highlighting effect of HFD (in intact (Cre+ve) animals) of the 863 REVERBα target genes from A(iii). Metabolic map illustrating REVERBα targets (C). Genes showing significantly down-regulation by HFD (in Cre+ve animals) are starred*.

**FIGURE 6. REVERBα-regulated targets, unmasked by obesity, associate with gWAT REVERBα binding sites.**
A. Schematic of peaks-genes analysis. ChIP-seq peaks are extended by user-specified distances (λ) either side of the peak centre. Enrichment of the genes of interest, within all genes whose transcription start site (TSS) is detected within λ, is assessed by a hypergeometric test. The TSS of *Pnpla5*, for example, lies within 10kbp of a REVERBα ChIP-seq peak. B. Proposed model. In normal conditions, there is a large number of genes over which REVERBα repressive control is not apparent, likely because the regulatory environment (chromatin state, presence of other regulators) blocks this interaction or renders it redundant. In obese adipose, alterations to the regulatory environment (e.g. chromatin remodelling) are permissive to REVERBα activity.
DISCUSSION

We set out to define the role of REVERBα in the regulation of white adipose tissue metabolism, and subsequently reveal a new understanding of REVERBα function. Together, our data show REVERBα to be a state-dependent regulator of WAT metabolism, with its widespread repressive action only unmasked by diet-induced obesity. Surprisingly, Reverbα expression in WAT appears to limit the energy buffering function of the tissue. This finding parallels our recent work in the liver (Hunter et al., 2020). Hepatic-selective loss of REVERBα carries no metabolic consequence, with REVERBα-dependent control over hepatic energy metabolism revealed only upon altered feeding conditions. Contrary to current understanding, our findings therefore suggest that REVERBα (and potentially other components of the peripheral clock) does not impose rhythmic repression of metabolic circuits under basal conditions, but rather determines tissue responses to altered metabolic state.

As reported previously by us and others (Delezie et al., 2012; Hand et al., 2015), global deletion of Reverbα leads to an increase in lipogenesis, adipose tissue expansion, and an exaggerated response to diet-induced obesity. How the loss of REVERBα specifically in WAT contributes to this phenotype has not previously been addressed. Here, we use proteomic, transcriptomic and lipid profiling studies to show a clear bias towards fatty acid synthesis and triglyceride storage within Reverbα-/- WAT. Adipocyte-targeted deletion of Reverbα reveals only a modest phenotype, and a relatively selective set of gene targets, limited to clock processes and collagen dynamics. These genes are concurrently de-regulated in Reverbα-/- adipose, and are found in proximity to REVERBα binding sites, strongly implicating them as direct targets of REVERBα repressive activity.

The reduced inflammation seen in obese ReverbαFlox2-αAdipoCre mice is likely multifactorial, but may be secondary to a reduction in the pro-inflammatory free fatty acid pool, resulting from de-repression of lipogenic and mitochondrial metabolism pathways, or the absence of signals.
from dead/dying adipocytes. It is of note that improved metabolic flexibility is proposed to be beneficial in other mouse models of metabolic disease (Jonker et al., 2012; Kim et al., 2007; Virtue et al., 2018) and in human obesity (Aucouturier et al., 2011; Begaye et al., 2020). We identify extracellular matrix as a new direct target of adipose REVERBα action; altered regulation of WAT collagen production and modification is also likely to contribute to the rapid and continued adipose tissue expansion and reduced obesity-related fibrosis. The clock has been linked to ECM re-modelling in other tissues (Chang et al., 2020; Dudek et al., 2015; Sherratt et al., 2019), where it is thought to coordinate ECM dynamics, collagen turnover and secretory processes (Chang et al., 2020). Adipose-specific deletion of Reverba now provides a unique model to explore the complex ECM responses which accompany obesity-related tissue hypertrophy and development of fibrosis.

A role for the clock in the regulation of WAT function has been reported in the literature (Barnea et al., 2015; Paschos et al., 2012; Shostak et al., 2013), perhaps implying that it is the rhythmicity conferred by the clock which is important for WAT metabolism. However, despite robust rhythms of clock genes persisting, rhythmic gene expression in gWAT is largely attenuated following genetic disruption of SCN function (Kolbe et al., 2016). This supports the alternative notion that an intact local clock is not the primary driver of rhythmic peripheral tissue metabolism. Indeed, metabolic processes, including lipid biosynthesis, were highly enriched in the cohort of SCN-dependent rhythmic genes from this study (Kolbe et al., 2016), implying that feeding behaviour and WAT responses to energy flux are more important than locally-generated rhythmicity for adipose function.

The modest impact of adipose-selective Reverba deletion is both at odds with the large effect of global Reverba deletion, and with the extensive WAT cistrome identified for REVERBα (even by stringent peak calling as we have done here). This suggests that the tissue-specific actions of REVERBα are necessary, but not sufficient, and require additional regulation from the metabolic state. Although not explored to the same extent, a lipogenic phenotype of liver-
specific RORα/γ deletion has previously been shown to be unmasked by HFD-feeding (Zhang et al., 2017). By driving adipose tissue hypertrophy through HFD-feeding of the \textit{Reverba}^{\text{Flox2-}}\text{Adipo}^{\text{Cre}}\text{mice, we observed a stark difference in the adipose phenotype of targeted mice and littermate controls. WAT tissue lacking \textit{Reverba} showed significantly increased tissue expansion, but little evidence of normal obesity-related pathology (tissue fibrosis, and immune cell infiltration/inflammation). Genes controlling mitochondrial activity, lipogenesis and lipid storage were relatively spared from the obesity-related down-regulation observed in control mouse tissue, and were associated with the WAT \textit{REVERBα} cistrome. Thus, in response to HFD-feeding, \textit{REVERBα} acts to repress metabolic activity in the adipocyte and limit tissue expansion (albeit at the eventual cost of tissue dysfunction, inflammation and development of adipose fibrosis).

The broadening of \textit{REVERBα}’s regulatory influence in response to obesity likely reflects a change to the chromatin environment in which \textit{REVERBα} operates (\textbf{Figure 6 Supplementary B}). The majority of emergent \textit{REVERBα} target genes are repressed in obese adipose when \textit{Reverba} expression is intact (\textbf{Figure 6B}). As these genes are not de-repressed by \textit{Reverba} loss in normal adipose, \textit{REVERBα} activity must be redundant or ineffective in a ‘basal’ metabolic state. Subsequent emergence of \textit{REVERBα}’s transcriptional control may reflect alterations in chromatin accessibility or organisation, and/or the presence of transcriptional repressors and accessory factors required for full activity. As \textit{REVERBα} is itself proposed to regulate enhancer-promoter loop formation (Kim et al., 2018), modulation of \textit{Reverba} expression would be a further important variable here. Such reshaping of the regulatory landscape likely occurs across tissues, and may explain why, with metabolic challenge, emergent circadian rhythmicity is observed in gene expression (Eckel-Mahan et al., 2013; Kinouchi et al., 2018; Tognini et al., 2017), and in circulating and tissue metabolites (Dyar et al., 2018; Eckel-Mahan et al., 2013).
Here, we now uncover a role for REVERBα in limiting the energy-buffering role of WAT, a discovery which may present therapeutic opportunity as we cope with an epidemic of human obesity. Despite recent findings which have cast doubt on the utility of some of the small molecule REVERBα ligands (Dierickx et al., 2019), antagonising WAT REVERBα now emerges as a potential target in metabolic disease. Finally, our study suggests that a functioning circadian clock may be beneficial in coping with acute mistimed metabolic cues but, that under chronic energy excess, may contribute to metabolic dysfunction and obesity-related pathology.
MATERIALS AND METHODS

Animal experiments. All experiments described here were conducted in accordance with local requirements and licenced under the UK Animals (Scientific Procedures) Act 1986, project licence number 70/8558 (DAB). Procedures were approved by the University of Manchester Animal Welfare and Ethical Review Body (AWERB). Unless otherwise specified, all animals had ad libitum access to standard laboratory chow and water, and were group-housed on 12-hour:12-hour light:dark (LD) cycles and ambient temperature of 22°C±1.5°C. Male mice (Mus musculus) were used for all experimental procedures. All proteomics studies were carried out on 13-week-old weight matched males. RNA-seq studies for Figure 3 were carried out on 12-14 week-old weight-matched males; the RNA-seq study for Figure 5 was carried out on 28 week-old males (following 16 weeks of high-fat diet or normal chow feeding).

Reverba<sup>α</sup>

Reverba<sup>α</sup> mice were originally generated by Ueli Schibler (University of Geneva) (Preitner et al., 2002). These mice were created by replacing exons 2-5 of the Reverba gene by an in-frame LacZ allele. Mice were then imported to the University of Manchester and backcrossed to C57BL/6J mice.

Reverba<sup>Flox<sub>2-6</sub></sup>

A CRISPR-Cas9 approach was used to generate a conditional knock allele for Nr1d1 (Reverba), as described (Hunter et al., 2020). LoxP sites were integrated, in a two-step process, at intron 2 and intron 6, taking care to avoid any previously described transcriptional regulatory sites (Yamamoto et al., 2004). A founder animal with successful integration of both the 5' and 3' loxP sites, transmitting to the germline, was identified and bred forward to establish a colony.

Reverba<sup>Flox<sub>2-6</sub> Adipo<sup>Cre</sup></sup>
Adiponectin-driven Cre-recombinase mice (Eguchi et al., 2011; Jeffery et al., 2014) were purchased from The Jackson Laboratory and subsequently bred against the Reverbα<sup>Flox2-6</sup> at the University of Manchester.

In vivo phenotyping. Body composition of mice was analysed prior to cull by quantitative magnetic resonance (EchoMRI 900). Energy expenditure was measured via indirect calorimetry using CLAMS (Columbus Instruments) for 10-12 week old male mice. Mice were allowed to acclimatise to the cages for two days, prior to an average of 5 days of recordings being collected. Recording of body temperature and activity was carried out via surgically implanted radiotelemetry devices (TA-F10, Data Sciences International). Data is shown as a representative day average of single-housed age-matched males. For the diet challenge, male mice were fed high-fat diet (HFD; 60% energy from fat; DIO Rodent Purified Diet, IPS Ltd) for a period of 10-16 weeks from 12 weeks of age. Blood glucose was measured from tail blood using the Aviva Accuchek meter (Roche). For the insulin tolerance test, mice were fasted from ZT0, then injected with 0.75 IU/kg human recombinant insulin (I2643, Sigma Aldrich) at ZT6 (time “0 minutes”).

Insulin ELISA. Insulin concentrations were measured by ELISA (EZRMI-13K Rat/Mouse insulin ELISA, Merck Millipore) according to the manufacturer’s instructions. Samples were diluted in matrix solution to fall within the range of the assay. Internal controls supplied with the kit were run alongside the samples and were in the expected range.

Histology. gWAT was collected and immediately fixed in 4% paraformaldehyde for 24 hours, transferred into 70% ethanol, and processed using a Leica ASP300 S tissue processor. 5μm sections underwent H&E staining (Alcoholic Eosin Y solution (HT110116) and Harris Haematoxylin solution (HHS16), Sigma Aldrich), Picrosirius Red staining (see below), or F4/80 immunohistochemistry (see below), prior to imaging using a Snapshots Olympus single slide scanner at 10x or 20x objective magnification alongside Olympus cellSens Dimension.
software (version 1.18). Percentage area stained was quantified using ImageJ (version 1.52a) as detailed in the online ImageJ documentation (https://imagej.nih.gov/ij/docs/examples/stained-sections/index.html), with 5-12 images quantified per animal. Adipocyte area was quantified using the Adiposoft ImageJ plug-in (version 1.16 - https://imagej.net/Adiposoft).

For Picosirius Red staining, sections were dewaxed and rehydrated using the Leica ST5010 Autostainer XL. Sections were washed in distilled water and then transferred to Picosirius Red (Direct Red 80, Sigma Aldrich) (without the counterstain) for 1 hour. Sections were then washed briefly in 1% acetic acid. Sections were then dehydrated, cleared and mounted using the Leica ST5010 Autostainer XL.

For F4/80 immunohistochemistry, sections were dewaxed and rehydrated prior to enzymatic antigen retrieval (trypsin from porcine pancreas (T7168, Sigma)). Sections were treated with 3% hydrogen peroxide to block endogenous peroxidase activity followed by further blocking with 5% goat serum. Rat mAb to F4/80 (1:500) (ab6640, Abcam) was added and sections were incubated overnight at 4°C. Sections were washed before addition of the biotinylated anti-rat IgG (BA-9400, H&L) secondary antibody (1:1500) for 1 hour. Sections were developed using VECTAStain® Elite® ABC kit peroxidase, followed by DAB Peroxidase substrate (Vector Labs) and counterstained with haematoxylin. Slides were then dehydrated, cleared and mounted.

**Lipid extraction and gas chromatography.** Total lipid was extracted from tissue lysates using chloroform-methanol (2:1; v/v) according to the Folch method (Folch et al., 1957). An internal standard (tripentadecanoin glycerol (15:0)) of known concentration of was added to samples for quantification of total triacylglyceride. Lipid fractions were separated by solid-phase extraction and fatty acid methyl esters (FAMEs) were prepared as previously described (Heath et al., 2003). Separation and detection of total triglyceride FAMEs was achieved using
a 6890N Network GC System (Agilent Technologies; CA, USA) with flame ionization detection.

514 FAMEs were identified by their retention times compared to a standard containing 31 known fatty acids and quantified in micromolar from the peak area based on their molecular weight. The micromolar quantities were then totalled and each fatty acid was expressed as a percentage of this value (molar percentage; mol%).

519

Proteomics. Mice were culled by cervical dislocation and the gWAT was immediately removed and washed twice in ice-cold PBS and then once in ice-cold 0.25M sucrose, prior to samples being snap-frozen in liquid nitrogen and stored at -80°C. To extract the protein, the samples were briefly defrosted on ice and then cut into 50mg pieces and washed again in ice-cold PBS. The sample was then lysed in 200μl of 1M Triethylammonium bicarbonate buffer (TEAB; Sigma) with 0.1% (w/v) sodium dodecyl sulphate (SDS) with a Tissue Ruptor (Qiagen). Samples were centrifuged for 5 minutes, full speed, at 4°C and the supernatant collected into a clean tube. A Biorad protein assay (Biorad) was used to quantify the protein and Coomassie protein stain (InstantBlue™ Protein Stain Instant Blue, Expeoden) to check the quality of extraction. Full methods of subsequent iTRAQ proteomic analysis including bioinformatic analysis has been published previously (Xu et al., 2019). Here the raw data was searched against the mouse Swissprot database (release October 2017) using the paragon algorithm on Protein-Pilot (Version 5.0.1, AB SCIEX). A total of 33847 proteins were searched. As described (Xu et al., 2019), Bayesian protein-level differential quantification was performed by Andrew Dowsey (University of Bristol) using their own BayesProt (version 1.0.0), with default choice of priors and MCMC settings. Expression fold change relative to the control groups were determined and proteins with a global false discovery rate of >0.05 were deemed significant.

3T3-L1 cells. 3T3-L1 cells (ATCC) were maintained in Dulbecco's Modified Eagle's Medium - high glucose (DMEM/D6429, Sigma-Aldrich) supplemented with 10% Foetal Bovine Serum and 1% penicillin/streptomycin at 37°C/5% CO2. Cells were grown until confluent, passaged
and plated into 12-well tissue culture plates for differentiation. The differentiation protocol was initiated 5 days later. Cells were treated with 10µg/mL insulin (Sigma-Aldrich), 1µM dexamethasone (Sigma-Aldrich), 1µM rosiglitazone (AdooQ Bioscience) and 0.5mM IBMX (Sigma-Aldrich) prepared in DMEM + 10% FBS + 1% Pen/Strep for 3 days. On day 3 and day 5 the cell culture media was changed to 10µg/mL insulin and 1µM rosiglitazone in DMEM + 10% FBS + 1% Pen/Strep. On day 7, the cell culture media was changed to 10µg/mL insulin in DMEM + 10% FBS + 1% Pen/Strep. Finally on day 10, the cell culture media was changed to DMEM + 10% FBS + 1% Pen/Strep without any additional differentiation mediators. Cells were used from day 11 onwards. Lipid droplets were visible by day 5.

For knockdown studies, mature 3T3-L1 adipocytes were transfected with Sicontrol (Control ON-TARGETplus siRNA, Dharmacon), SiReverbα (Mouse NR1D1 ON-TARGETplus siRNA, Dharmacon) or SiReverbβ (Mouse NR1D2 ON-TARGETplus siRNA, Dharmacon) at 50nM concentration using Lipofectamine RNAiMAX (Invitrogen) as a transfection reagent. Briefly, 12-well plates were coated with poly-L-lysine hydrobromide (Sigma) and incubated for 20-30 minutes prior to excess poly-L-lysine being removed and the plates allowed to dry. SiRNAs and RNAiMAX transfection reagent were separately mixed with reduced serum media (OptiMEM, Gibco). The control or Reverbα/β SiRNA was then added to each well and mixed with an equal quantity of RNAiMAX and then incubated for 5 minutes at room temperature. Mature 3T3-L1 adipocytes were trypsinised (trypsin-EDTA solution, Sigma) and resuspended in FBS without P/S prior to being re-plated into the wells containing the SiRNA. After 24 hours the transfection mix was removed and replaced with DMEM without FBS or P/S. The cells were then collected 48 hours after transfection.

RNA extraction (cells). RNA was extracted from cells using the ReliaPrep™ RNA Cell Miniprep system (Promega, UK), following manufacturer’s instructions. RNA concentration and quality was determined with the use of a NanoDrop spectrophotometer and then stored at -80°C.
RNA extraction (tissue). Frozen adipose tissue was homogenised in TRIzol Reagent (Invitrogen) using Lysing Matrix D tubes (MP Biomedicals) and total RNA extracted according to the manufacturer’s TRIzol protocol. To remove excess lipid, samples then underwent an additional centrifugation (full speed, 5 minutes, room temperature) prior to chloroform addition. For the RNA sequencing samples the isopropanol phase of TRIzol extraction was transferred to Reliaprep tissue Miniprep kit (Promega, USA) columns to ensure high quality RNA samples were used. The column was then washed, DNAse treated and RNA eluted as per protocol. RNA concentration and quality was determined with the use of a NanoDrop spectrophotometer and then stored at -80°C. For RNA-seq, RNA was diluted to 1000ng in nuclease-free water to a final volume of 20uL.

RT-qPCR. For RT-qPCR, samples were DNase treated (RQ1 RNase-Free DNase, Promega, USA) prior to cDNA conversion High Capacity RNA-to-cDNA kit (Applied Biosystems). qPCR was performed using a GoTaq qPCR Master Mix (Promega, USA) and primers listed in Supplementary Table 1 using a Step One Plus (Applied Biosystems) qPCR machine. Relative quantities of gene expression were determined using the [delta][delta] Ct method and normalised with the use of a geometric mean of the housekeeping genes Hprt, Ppib and Actb. The fold difference of expression was calculated relative to the values of control groups.

RNA-seq. Adipose tissue was collected from adult male mice (n=6-8 per group) at ZT8 and flash-frozen. Total RNA was extracted and DNase-treated as described above. Biological replicates were taken forward individually to library preparation and sequencing. For library preparation, total RNA was submitted to the Genomic Technologies Core Facility (GTCF). Quality and integrity of the RNA samples were assessed using a 2200 TapeStation (Agilent Technologies) and then libraries generated using the TruSeq® Stranded mRNA assay (Illumina, Inc.) according to the manufacturer’s protocol. Briefly, total RNA (0.1-4μg) was used as input material from which polyadenylated mRNA was purified using poly-T, oligo-attached,
magnetic beads. The mRNA was then fragmented using divalent cations under elevated temperature and then reverse transcribed into first strand cDNA using random primers. Second strand cDNA was then synthesised using DNA Polymerase I and RNase H. Following a single ‘A’ base addition, adapters were ligated to the cDNA fragments, and the products then purified and enriched by PCR to create the final cDNA library. Adapter indices were used to multiplex libraries, which were pooled prior to cluster generation using a cBot instrument. The loaded flow-cell was then paired-end sequenced (76 + 76 cycles, plus indices) on an Illumina HiSeq4000 instrument. Finally, the output data was demultiplexed (allowing one mismatch) and BCL-to-Fastq conversion performed using Illumina’s bcl2fastq software, version 2.17.1.14

**RNA-seq data processing & differential gene expression analysis.** Paired-end RNA-seq reads were quality assessed using FastQC (v 0.11.3), FastQ Screen (v 0.9.2) (Wingett and Andrews, 2018). Reads were processed with Trimmomatic (v 0.36) (Bolger et al., 2014) to remove any remaining sequencing adapters and poor quality bases. RNA-seq reads were then mapped against the reference genome (mm10) using STAR (version 2.5.3a) (Dobin et al., 2013). Counts per gene (exons) were calculated by STAR using the genome annotation from GENCODEM16. Differential expression analysis was then performed with edgeR (Robinson et al., 2010) using QLF-tests based on published code (Chen et al., 2016). Changes were considered significant if they reached a FDR cut-off of <0.05. Interaction analysis was performed with stageR (Van den Berge et al., 2017) in conjunction with Limma voom (Law et al., 2014), setting alpha at 0.05.

**Published ChIP-seq.** Raw gWAT ChIP-seq data (Zhang et al., 2015) was downloaded from the GEO Sequence Read Archive (GSE67973) using the sratoolkit package (v2.9.2) (`fastq-dump` tool). The following datasets were used: REVERBo ZT10 ChIP-seq (two replicates) - SRR1977510, SRR1977511 – and ZT10 input raw data - SRR1977512. Reads were aligned to the mm10 genome with Bowtie2 (v.2.3.4.3) (Langmead and Salzberg, 2012), then sorted, indexed BAM files were produced with SAMtools (v.1.9) (Li et al., 2009). MACS2 (Zhang et
al., 2008) was used to call peaks from the experimental BAM files (-t) against the input control BAM file (-c), with the following options specified: `-f BAMPE --keep-dup=1 -q 0.01 --bdg --SPMR --verbose 0`. High-stringency peaks were defined as those with >7.5 fold-enrichment over input.

**Integrating RNA-seq and ChIP-seq.** In order to calculate enrichment of RNA-seq-based gene clusters with respect to ChIP-seq peaks, we used our in-house custom tool (Yang et al., 2019) which calculates gene cluster enrichment within specified distances from the centre of peaks (see also Code Availability statement below). The tool extends peaks in both directions for the given distances and extracts all genes whose TSSs overlap with the extended peaks. Given these genes, the inputted RNA-seq-based gene cluster, and the overlap of these two groups, it performs a hypergeometric test with the total number of genes in the mm10 genomes as background.

**Pathway analysis.** Pathway enrichment analysis of ENTREZ gene identifiers, either extracted from RNA-seq or proteomics data, was carried out using the R Bioconductor package ReactomePA (Yu and He, 2016). The `enrichPathway` tool was used with the following parameters: `organism = "mouse", pAdjustMethod = "BH", maxGSSize = 2000, readable = FALSE`. We considered pathways with a Padj<0.01 to be significantly enriched. For Figure S3A, no pathways had Padj<0.01 (likely due to the small number of inputted genes), hence we show the 5 pathways with the smallest Padj values.

**Protein extraction and Western blotting.** Small pieces (<100mg) of tissue were homogenised with the FastPrep Lysing Matrix D system (MP Biomedicals) in T-PER (Thermo Fisher Scientific), supplemented with protease inhibitor cocktail (Promega) at 1:50 dilution. Benzonase nuclease (EMD Millipore) was added (2μl), the homogenate briefly vortexed, then incubated on ice for 10 minutes. Homogenates were then centrifuged for 8 minutes at 10,000g, at 4°C, and the supernatant removed (avoiding any lipid layer). Protein concentration was
quantified using the Bio-Rad Protein Assay (Bio-Rad). For Western blotting, equal quantities (75μg for detection of REVERBα) of protein were added to 4x NuPAGE LDS sample buffer (Invitrogen), NuPAGE sample reducing agent (dithiothreitol) (Invitrogen) and water, and denatured at 70°C for 10 minutes. Samples were run on 4-20% Mini-PROTEAN TGX Precast Protein Gels (Bio-Rad) before wet transfer to nitrocellulose membranes. Membranes were blocked with Protein-Free Blot Blocking Buffer (Azure Biosystems), and subsequent incubation and wash steps carried out following manufacturer’s instructions. Primary and secondary antibodies used were as listed in Supplementary Table 2, with primary antibodies being used at a 1:1000 dilution and secondary antibodies at 1:10,000. Membranes were imaged using chemiluminescence or the LI-COR Odyssey system. Uncropped blot images can be provided by the corresponding author upon request.

Statistics. To compare two or more groups, t-tests or ANOVAs were carried out using GraphPad Prism (v.8.4.0). For all of these, the exact statistical test used and n numbers are indicated in the figure legends. All n numbers refer to individual biological replicates (ie. individual animals). Unless otherwise specified, bar height is at mean, with error bars indicating +/-SEM. In these tests, significance is defined as *P<0.05 or **P<0.01 (P values below 0.01 were not categorised separately, i.e. no more than two stars were used, as we deemed this to be a meaningful significance cut-off). Statistical analyses of proteomics, RNA-seq and ChIP-seq data were carried out as described above in Methods, using the significance cut-offs mentioned. Plots were produced using GraphPad Prism or R package ggplot2.

Data availability. RNA-seq data generated in the course of this study has been uploaded to ArrayExpress and is available at http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-8840. Raw proteomics data has been uploaded to Mendeley Data (https://data.mendeley.com/datasets/wskyz3rhsg/draft?a=ef40a1ec-36a4-4509-979d-32d494b96585). Other data supporting the findings of this study are available from the corresponding author upon reasonable request.
Code availability. The custom Python code (Yang et al., 2019) used to carry out the peaks-genes enrichment analysis in this study is available at http://bartzabel.ls.manchester.ac.uk//Pete/PF5HZns0zv/pegs-0.2.0.tgz.
ACKNOWLEDGEMENTS & AUTHOR CONTRIBUTIONS

Acknowledgements: We thank Rachel Scholey, I-Hsuan Lin, Ping Wang and Peter Briggs (Bioinformatics Core Facility, UoM), and Thea Danby (Faculty of Biology, Medicine and Health, UoM) for statistical and technical assistance, and acknowledge support of core facilities at the University of Manchester: Genomic Technologies Core Facility, Biological Services Unit, and Histological Services Unit. We also acknowledge and thank the support of our funders: the BBSRC (BB/I018654/1 to D.A.B.), the MRC (Clinical Research Training Fellowship MR/N021479/1 to A.L.H.; MR/P00279X/1 to D.A.B; MR/P011853/1 and MR/P023576/1 to D.W.R.), and the Wellcome Trust (107849/Z/15/Z, 107851/Z/15/Z).

Author Contributions: Conceptualisation, A.L.H., C.E.P., D.W.R., D.A.B.; Methodology, A.A., R.D.U., D.W.R., D.A.B.; Software, M.I., A.L.H.; Investigation, A.L.H., C.E.P., P.D., T.C., P.S.C., N.J.B., R.C.N.; Formal Analysis, A.L.H., C.E.P., R.D.U., L.H., M.I., D.A.B.; Writing, A.L.H., C.E.P., A.S.I.L., D.W.R., D.A.B.; Funding Acquisition, A.L.H., D.W.R., D.A.B.; Supervision, D.A.B.

Declaration of Interests: The authors declare no competing interests.
REFERENCES

Aucouturier J, Duché P, Timmons BW. 2011. Metabolic flexibility and obesity in children and youth. *Obes Rev* **12**:e44–e53. doi:10.1111/j.1467-789X.2010.00812.x

Barnea M, Chapnik N, Genzer Y, Froy O. 2015. The circadian clock machinery controls adiponectin expression. *Mol Cell Endocrinol* **399**:284–287. doi:10.1016/j.mce.2014.10.018

Bass J, Takahashi JS. 2010. Circadian integration of metabolism and energetics. *Science* (80- ). doi:10.1126/science.1195027

Begaye B, Vinales KL, Hollstein T, Ando T, Walter M, Bogardus C, Krakoff J, Piaggi P. 2020. Impaired metabolic flexibility to high-fat overfeeding predicts future weight gain in healthy adults. *Diabetes* **69**:181–192. doi:10.2337/db19-0719

Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* **30**:2114–2120. doi:10.1093/bioinformatics/btu170

Broussard JL, Cauter E Van. 2016. Disturbances of sleep and circadian rhythms: Novel risk factors for obesity. *Curr Opin Endocrinol Diabetes Obes*. doi:10.1097/MED.0000000000000276

Bugge A, Feng D, Everett LJ, Briggs ER, Mullican SE, Wang F, Jager J, Lazar MA. 2012. Rev-erbalpha and Rev-erbbeta coordinately protect the circadian clock and normal metabolic function. *Genes Dev* **26**:657–667. doi:10.1101/gad.186858.112

Chang J, Garva R, Pickard A, Yeung CYC, Mallikarjun V, Swift J, Holmes DF, Calverley B, Lu Y, Adamson A, Raymond-Hayling H, Jensen O, Shearer T, Meng QJ, Kadler KE. 2020. Circadian control of the secretory pathway maintains collagen homeostasis. *Nat Cell Biol* **22**:74–86. doi:10.1038/s41556-019-0441-z

Chawla A, Lazar MA. 1993. Induction of Rev-ErbAα, an orphan receptor encoded on the opposite strand of the α-thyroid hormone receptor gene, during adipocyte differentiation. *J Biol Chem* **268**:16265–16269.

Chen Y, Lun ATL, Smyth GK. 2016. From reads to genes to pathways: differential expression
analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline. *F1000Research* **5**:1438. doi:10.12688/f1000research.8987.2

Damiola F, Le Minli N, Preitner N, Kornmann B, Fleury-Olela F, Schibler U. 2000. Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. *Genes Dev* **14**:2950–2961. doi:10.1101/gad.183500

Delezie J, Dumont S, Dardente H, Oudart H, Grechez-Cassiau A, Klosen P, Teboul M, Delaunay F, Pevet P, Challet E. 2012. The nuclear receptor REV-ERBalpha is required for the daily balance of carbohydrate and lipid metabolism. *FASEB J* **26**:3321–3335. doi:10.1096/fj.12-208751

Dibner C, Schibler U, Albrecht U. 2010. The Mammalian Circadian Timing System: Organization and Coordination of Central and Peripheral Clocks. *Annu Rev Physiol* **72**:517–549. doi:10.1146/annurev-physiol-021909-135821

Dierickx P, Emmett MJ, Jiang C, Uehara K, Liu M, Adlanmerini M, Lazar MA. 2019. SR9009 has REV-ERB–independent effects on cell proliferation and metabolism. *Proc Natl Acad Sci* **116**:12147–12152. doi:10.1073/pnas.1904226116

Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. 2013. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**:15–21. doi:10.1093/bioinformatics/bts635

Dudek M, Gossan N, Yang N, Im H-J, Ruckshanthi JPD, Yoshitane H, Li X, Jin D, Wang P, Boudiffa M, Bellantuono I, Fukada Y, Boot-Handford RP, Meng Q-J. 2015. The chondrocyte clock gene Bmal1 controls cartilage homeostasis and integrity. *J Clin Invest* **126**:365–376. doi:10.1172/JCI82755

Dyar KA, Lutter D, Artati A, Ceglia NJ, Liu Y, Armenta D, Jastroch M, Schneider S, de Mateo S, Cervantes M, Abbondante S, Tognini P, Orozco-Solis R, Kinouchi K, Wang C, Swerdloff R, Nadeef S, Masri S, Magistretti P, Orlando V, Borrelli E, Uhlenhaut NH, Baldi P, Adamski J, Tschöp MH, Eckel-Mahan K, Sassone-Corsi P. 2018. Atlas of Circadian Metabolism Reveals System-wide Coordination and Communication between Clocks. *Cell* **174**:1571-1585.e11. doi:10.1016/j.cell.2018.08.042
Eckel-Mahan KL, Patel VR, De Mateo S, Orozco-Solis R, Ceglia NJ, Sahar S, Dilag-Penilla SA, Dyar KA, Baldi P, Sassone-Corsi P. 2013. Reprogramming of the circadian clock by nutritional challenge. Cell 155:1464–1478. doi:10.1016/j.cell.2013.11.034

Eguchi J, Wang X, Yu S, Kershaw EE, Chiu PC, Dushay J, Estall JL, Klein U, Maratos-Flier E, Rosen ED. 2011. Transcriptional Control of Adipose Lipid Handling by IRF4. Cell Metab 13:249–259. doi:10.1016/j.cmet.2011.02.005

Feng D, Liu T, Sun Z, Bugge A, Mullican SE, Alenghat T, Liu XS, Lazar MA. 2011. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism.

Science (80-) 331:1315–1319. doi:10.1126/science.1198125

Folch J, Lees M, Sloane Stanley GH. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497–509.

Gerhart-Hines Z, Feng D, Emmett MJ, Everett LJ, Loro E, Briggs ER, Bugge A, Hou C, Ferrara C, Seale P, Pryma DA, Khurana TS, Lazar MA. 2013. The nuclear receptor Rev-erba controls circadian thermogenic plasticity. Nature 503:410–413. doi:10.1038/nature12642

Goldstein I, Baek S, Presman DM, Paakinaho V, Swinstead EE, Hager GL. 2017. Transcription factor assisted loading and enhancer dynamics dictate the hepatic fasting response. Genome Res 27:427–439. doi:10.1101/gr.212175.116

Guan D, Xiong Y, Borck PC, Jang C, Doulias P-T, Papazyan R, Fang B, Jiang C, Zhang Y, Briggs ER, Hu W, Steger D, Ischiropoulos H, Rabinowitz JD, Lazar MA. 2018. Diet-Induced Circadian Enhancer Remodeling Synchronizes Opposing Hepatic Lipid Metabolic Processes. Cell 174:831-842.e12. doi:10.1016/j.cell.2018.06.031

Guo H, Brewer JM, Champhekar A, Harris RBS, Bittman EL. 2005. Differential control of peripheral circadian rhythms by suprachiasmatic-dependent neural signals. Proc Natl Acad Sci 102:3111–3116. doi:10.1073/pnas.0409734102

Hand LE, Usan P, Cooper GJS, Xu LY, Ammori B, Cunningham PS, Aghamohammadzadeh R, Soran H, Greenstein A, Loudon ASI, Bechtold DA, Ray DW. 2015. Adiponectin Induces A20 Expression in Adipose Tissue to Confer Metabolic Benefit. Diabetes
Heath RB, Karpe F, Milne RW, Burdge GC, Wootton SA, Frayn KN. 2003. Selective partitioning of dietary fatty acids into the VLDL TG pool in the early postprandial period. J Lipid Res 44:2065–2072. doi:10.1194/jlr.M300167-JLR200

Hughes ME, Hong H-K, Chong JL, Indacochea AA, Lee SS, Han M, Takahashi JS, Hogenesch JB. 2012. Brain-specific rescue of Clock reveals system-driven transcriptional rhythms in peripheral tissue. PLoS Genet 8:e1002835. doi:10.1371/journal.pgen.1002835

Hunter AL, Pelekanou CE, Adamson A, Downton P, Barron NJ, Cornfield T, Poolman TM, Humphreys N, Cunningham PS, Hodson L, Loudon AS, Iqbal M, Bechtold DA, Ray DW. 2020. Nuclear receptor REVERBα is a state-dependent regulator of liver energy metabolism. Proc Natl Acad Sci U S A in press. doi:10.1073/pnas.2005330117

Jager J, Wang F, Fang B, Lim H-W, Peed LC, Steger DJ, Won K-J, Kharitonenkova A, Adams AC, Lazar MA. 2016. The Nuclear Receptor Rev-erba Regulates Adipose Tissue-specific FGF21 Signaling. J Biol Chem 291:10867–75. doi:10.1074/jbc.M116.719120

Jeffery E, Berry R, Church CD, Yu S, Shook BA, Horsley V, Rosen ED, Rodeheffer MS. 2014. Characterization of Cre recombinase models for the study of adipose tissue. Adipocyte 3:206–211. doi:10.4161/adip.29674

Jonker JW, Suh JM, Atkins AR, Ahmadian M, Li P, Whyte J, He M, Jugulion H, Yin YQ, Phillips CT, Yu RT, Olefsky JM, Henry RR, Downes M, Evans RM. 2012. A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 485:391–394. doi:10.1038/nature10998

Kim HJ, Choi S, Kim Kyuwoong, Park H, Kim Kyae-hyung, Park SM, Jun H, Choi S, Kim Kyuwoong, Park H, Kim HJ. 2019. Association between misalignment of circadian rhythm and obesity in Korean men: Sixth Korea National Health and Nutrition Examination Survey Association between misalignment of circadian rhythm and obesity in Korean men: Sixth Korea National Health and. Chronobiol Int 00:1–9. doi:10.1080/07420528.2019.1671439
Kim JY, Van De Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T, Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, Deshaies Y, Shulman GI, Schwartz GJ, Scherer PE. 2007. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 117:2621–2637. doi:10.1172/JCI31021

Kim YH, Marhon SA, Zhang Y, Steger DJ, Won KJ, Lazar MA. 2018. Rev-erba dynamically modulates chromatin looping to control circadian gene transcription. Science (80-) 359:1274–1277. doi:10.1126/science.aao6891

Kinouchi K, Magnan C, Ceglia N, Liu Y, Cervantes M, Pastore N, Huynh T, Ballabio A, Baldi P, Masri S, Sassone-Corsi P. 2018. Fasting Imparts a Switch to Alternative Daily Pathways in Liver and Muscle. Cell Rep 25:3299-3314.e6. doi:10.1016/j.celrep.2018.11.077

Kolbe I, Husse J, Salinas G, Lingner T, Astiz M, Oster H. 2016. The SCN Clock Governs Circadian Transcription Rhythms in Murine Epididymal White Adipose Tissue. J Biol Rhythms 31:577–587. doi:10.1177/0748730416666170

Kornmann B, Schaad O, Bujard H, Takahashi JS, Schibler U. 2007. System-driven and oscillator-dependent circadian transcription in mice with a conditionally active liver clock. PLoS Biol 5:e34. doi:10.1371/journal.pbio.0050034

Koronowski KB, Kinouchi K, Welz PS, Smith JG, Zinna VM, Shi J, Samad M, Chen S, Magnan CN, Kinchen JM, Li W, Baldi P, Benitah SA, Sassone-Corsi P. 2019. Defining the Independence of the Liver Circadian Clock. Cell 177:1448–1462. doi:10.1016/j.cell.2019.04.025

Kumar N, Solt LA, Wang Y, Rogers PM, Bhattacharyya G, Kamenecka TM, Stayrook KR, Crumbley C, Floyd ZE, Gimble JM, Griffin PR, Burris TP. 2010. Regulation of adipogenesis by natural and synthetic REV-ERB ligands. Endocrinology 151:3015–3025. doi:10.1210/en.2009-0800

Lamia KA, Storch K-F, Weitz CJ. 2008. Physiological significance of a peripheral tissue circadian clock. Proc Natl Acad Sci 105:15172–7. doi:10.1073/pnas.0806717105

Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. Nat Methods
Law CW, Chen Y, Shi W, Smyth GK. 2014. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol* 15:R29. doi:10.1186/gb-2014-15-2-r29

Le Martelot G, Claudel T, Gatfield D, Schaad O, Kornmann B, Lo Sasso G, Moschetta A, Schibler U. 2009. REV-ERBα participates in circadian SREBP signaling and bile acid homeostasis. *PLoS Biol* 7:e1000181. doi:10.1371/journal.pbio.1000181

Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup. 2009. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25:2078–2079. doi:10.1093/bioinformatics/btp352

Masri S, Papagiannakopoulos T, Kinouchi K, Liu Y, Cervantes M, Baldi P, Jacks T, Sassone-Corsi P. 2016. Lung Adenocarcinoma Distally Rewires Hepatic Circadian Homeostasis. *Cell* 165:896–909. doi:10.1016/j.cell.2016.04.039

Mistlberger RE. 1994. Circadian food-anticipatory activity: formal models and physiological mechanisms. *Neurosci Biobehav Rev* 18:171–95.

Paschos GK, Ibrahim S, Song W-LL, Kunieda T, Grant G, Reyes TM, Bradfield CA, Vaughan CH, Eiden M, Masoodi M, Griffin JL, Wang F, Lawson JA, Fitzgerald GA. 2012. Obesity in mice with adipocyte-specific deletion of clock component Arntl. *Nat Med* 18:1768–1777. doi:10.1038/nm.2979

Preitner N, Damiola F, Luis-Lopez-Molina, Zakany J, Duboule D, Albrecht U, Schibler U. 2002. The Orphan Nuclear Receptor REV-ERBα Controls Circadian Transcription within the Positive Limb of the Mammalian Circadian Oscillator. *Cell* 110:251–260. doi:10.1016/S0092-8674(02)00825-5

Quagliarini F, Mir AA, Balazs K, Wierer M, Dyar KA, Jouffe C, Makris K, Hawe J, Heinig M, Filipp FV, Barish GD, Uhlenhaut NH. 2019. Cistromic Reprogramming of the Diurnal Glucocorticoid Hormone Response by High-Fat Diet. *Mol Cell* 76:531-545.e5. doi:10.1016/j.molcel.2019.10.007

Reinke H, Asher G. 2019. Crosstalk between metabolism and circadian clocks. *Nat Rev Mol
Robinson MD, McCarthy DJ, Smyth GK. 2010. edgeR: a Bioconductor package for
differential expression analysis of digital gene expression data. *Bioinformatics* **26**:139–140. doi:10.1093/bioinformatics/btp616

Sherratt MJ, Hopkinson L, Naven M, Hibbert SA, Ozols M, Eckersley A, Newton VL, Bell M,
Meng Q-J. 2019. Circadian rhythms in skin and other elastic tissues. *Matrix Biol.*
doi:10.1016/j.matbio.2019.08.004

Shostak A, Meyer-Kovac J, Oster H. 2013. Circadian regulation of lipid mobilization in white
adipose tissues. *Diabetes* **62**:2195–2203. doi:10.2337/db12-1449

Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, Lundasen T, Shin Y, Liu J, Cameron
MD, Noel R, Yoo S-H, Takahashi JS, Butler AA, Kamenecka TM, Burris TP. 2012.
Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists.
*Nature* **485**:62–8. doi:10.1038/nature11030

Tognini P, Murakami M, Liu Y, Eckel-Mahan KL, Newman JC, Verdin E, Baldi P, Sassone-
Corsi P. 2017. Distinct Circadian Signatures in Liver and Gut Clocks Revealed by
Ketogenic Diet. *Cell Metab* **26**:523-538.e5. doi:10.1016/j.cmet.2017.08.015

Van den Berge K, Soneson C, Robinson MD, Clement L. 2017. stageR: A general stage-
wise method for controlling the gene-level false discovery rate in differential expression
and differential transcript usage. *Genome Biol* **18**:151. doi:10.1186/s13059-017-1277-0

Virtue S, Petkevicius K, Moreno-Navarrete JM, Jenkins B, Hart D, Dale M, Koulman A,
Fernández-Real JM, Vidal-Puig A. 2018. Peroxisome Proliferator-Activated Receptor γ2
Controls the Rate of Adipose Tissue Lipid Storage and Determines Metabolic Flexibility.
*Cell Rep* **24**:2005-2012.e7. doi:10.1016/j.celrep.2018.07.063

West AC, Bechtold DA. 2015. The cost of circadian desynchrony: Evidence, insights and
open questions. *BioEssays* **37**:777–788. doi:10.1002/bies.201400173

Wingett SW, Andrews S. 2018. FastQ Screen: A tool for multi-genome mapping and quality
control. *F1000Research* **7**:1338. doi:10.12688/f1000research.15931.2

Xu J, Patassini S, Rustogi N, Riba-Garcia I, Hale BD, Phillips AM, Waldvogel H, Haines R,
Bradbury P, Stevens A, Faull RLM, Dowsey AW, Cooper GJS, Unwin RD. 2019. Regional protein expression in human Alzheimer’s brain correlates with disease severity. *Commun Biol* **2**:43. doi:10.1038/s42003-018-0254-9

Yamamoto T, Nakahata Y, Soma H, Akashi M, Mamine T, Takumi T. 2004. Transcriptional oscillation of canonical clock genes in mouse peripheral tissues. *BMC Mol Biol* **5**:18. doi:10.1186/1471-2199-5-18

Yang S-H, Andrabi M, Biss R, Baker SM, Iqbal M, Sharrocks AD. 2019. ZIC3 Controls the Transition from Naïve to Primed Pluripotency. *Cell Rep* **27**:3215–3227. doi:10.1016/j.celrep.2019.05.026

Yu G, He QY. 2016. ReactomePA: An R/Bioconductor package for reactome pathway analysis and visualization. *Mol Biosyst* **12**:477–479. doi:10.1039/c5mb00663e

Zhang Y, Fang B, Damle M, Guan D, Li Z, Kim YH, Gannon M, Lazar MA. 2016. HNF6 and Rev-erbalpha integrate hepatic lipid metabolism by overlapping and distinct transcriptional mechanisms. *Genes Dev* **30**:1636–1644. doi:10.1101/gad.281972.116

Zhang Y, Fang B, Emmett MJ, Damle M, Sun Z, Feng D, Armour SM, Remsberg JR, Jager J, Soccio RE, Steger DJ, Lazar MA. 2015. Discrete functions of nuclear receptor Rev-erbalpha couple metabolism to the clock. *Science (80-)* **348**:1488–1492. doi:10.1126/science.aab3021

Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nussbaum C, Myers RM, Brown M, Li W, Liu XS. 2008. Model-based Analysis of ChIP-Seq (MACS). *Genome Biol* **9**:R137. doi:10.1186/gb-2008-9-9-r137

Zhang Y, Papazyan R, Damle M, Fang B, Jager J, Feng D, Peed LC, Guan D, Sun Z, Lazar MA. 2017. The hepatic circadian clock fine-tunes the lipogenic response to feeding through RORα/γ. *Genes Dev* **31**:1202–1211. doi:10.1101/gad.302323.117
### SUPPLEMENTARY TABLE 1 - qPCR primer sequences

| Gene | Forward Primer (5’-3’) | Reverse Primer (5’-3’) |
|------|------------------------|------------------------|
| Acaca | TAATGGGCTGCCTTGCTTGACTC | TCAATATCGCACTCACTCTTTG |
| Acss3 | AATGTCGCAAAGTAACAGGCAG | GTGGTCTTTGACCTCCCCACACC |
| Actb | GGCTGTTTCCTGGCTGACTC | TCAATATGCCCACTCACTCTTTG |
| Bmal1 | GTGCAATGTTGCCAGGAGGAA | GGGAGGCGTACTTGTGATGTTC |
| Cd36 | CCACAGTTGGTGTGTTTTATCC | TCAATTATGCCAACTTGGCTT |
| Col1a1 | TCCCAACATCAGCTACACCTACAC | CTCTTGCCCTTGCTCTGAG |
| Col5a3 | TACCTCTGCTACGGGCTGCT | CTTTTGCTCCCTCATCACCC |
| Col6a1 | TGCTGCTGTGGATCTATTTCGG | CTGCTCGCTCGCTGTAATGT |
| Col6a2 | TGCTGCTGTGGATCTATTTCGG | CTGCTCGCTCGCTGTAATGT |
| Col6a3 | CTGCTGCTGTGGATCTATTTCGG | CTGCTCGCTCGCTGTAATGT |
| Dio2 | CCAGACAACATGCACCTGGCGT | GAAATGGCTGCCCCACAC |
| Elovl6 | GAGCAAGGGCCAGACAAAC | ATGCCGACACCAAAAGATAA |
| Fasn | CCCAGAGCTTTGTGCTGACTC | CGAATGGTCTGGCTTTG |
| G6pdx | AGACCTGCAAGATCGACTACAGC | TGGTTGACAGGTTGATTTG |
| Hprt | GTGGATACAGGCCAGACTTCGTG | GATTCAACTTTGCCTCATCTT |
| Loxl4 | TTGCTCTCAAGGCACTCCTTGTA | GCAGCGAACACTCTCATCA |
| Lpl | AGGGCTCCTGGCTGAGTTGTA | CCATCGCTCAACCCAGACAA |
| Me1 | GGGATTTCCTACATGTGGTGT | GTTCATGGGCAACACCTT |
| Pfk1 | TGCAAGCGCTACATCTTGCTCC | GTCAATGGTCGAGTGGTTG |
| Plin2 | AAGAGGCAAAACAAAAAGAGGCCAGGAGCA | ACCCTGAAATTTGCTGTTGCTGACGACTG |
| Ppib | GGAGATGGCCACAGAGGAGAA | CGGTAGTGCTCAGTTGGAAGTTT |
| Reverbα | GTCTCTCTTTGCGATGTCTT | CCAAGTTCATGGGCACCC |
| Reverbβ | CAGGAAGTGCTTATTGCTCAAC | GGACGAGGACTGGAAGCTAAT |
| Scd1 | CGCTGCTGTCCCTGGCTACTG | CAGCCAGGGCTGTTGAGGA |
| Ucp1 | ACTGCGACACTTCCAGTTG | CTGTGCCTCAGACTGAGT |

The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under an CC-BY 4.0 International license.
### SUPPLEMENTARY TABLE 2 – Antibodies

| Source and target              | Manufacturer       | Catalogue identifier, lot                        | Use                      |
|-------------------------------|--------------------|------------------------------------------------|--------------------------|
| Rabbit polyclonal anti-REVERBα (NR1D1) | ProteinTech        | Cat#14506-1-AP, lot 5745; RRID:AB_11182604       | Western blot, primary    |
| Mouse monoclonal anti-UCP1 (clone 536435) | R&D Systems        | Cat#MAB6158, lot CCNV0218091; RRID:AB_10572490   | Western blot, primary    |
| Mouse monoclonal anti-β-ACTIN (ACTB) | ProteinTech        | Cat#60008-1, lot 0001084; RRID:AB_2289225        | Western blot, primary    |
| Sheep Anti-Mouse IgG, HRP-linked whole Ab | GE Healthcare      | Cat#NA931V, lot 16908225; RRID:AB_772210         | Western blot, secondary  |
| Donkey Anti-Rabbit IgG, HRP-linked whole Ab | GE Healthcare      | Cat#NA934V, lot 16921443; RRID:AB_772206         | Western blot, secondary  |
| Goat polyclonal Anti-Rabbit IgG (H+L), DyLight 680 Conjugate | Cell Signaling Technology | Cat#5366P, lot 7; RRID:AB_10693812 | Western blot, secondary  |
| Rat monoclonal anti-F4/80 | Abcam              | Cat#ab6640, lot 845724; RRID:AB_1140040           | Immunohistochemistry, primary |
| Goat biotinylated anti-rat IgG (affinity purified) | H&L                | Cat#BA-9400, lot ZB1216; RRID:AB_2336202           | Immunohistochemistry, secondary |